Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Inside the UK’s campaign to reschedule psilocybin with MP Crispin Blunt; Awakn signs MOU with the NHS to increase accessibility of psychedelic medicines; DEA once again boosts psilocybin, MDMA and DMT production quotas
Psychedelic Healthcare: The Next Five Years; COMPASS Pathways shares update from Phase IIb clinical trial; Will the magic of psychedelics transform psychiatry?
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Will the UK be the first European country to embrace psilocybin-assisted therapy?; COMPASS shares COMP360 open-label study data; Where the psychedelic revolution is headed.
Numinus CEO, Payton Nyquvest, on the company’s growth and acquisition strategy; UK PM Boris Johnson to consider latest advice on legalisation of psilocybin; The DEA has proposed a surge in the production of psychedelic medicines.
Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on DMT’s power to treat Major Depressive Disorder; atai creates subsidiary to target depression with precision psychiatry; How COVID-19 opened the door to a new era in psychedelic medicine.
The Psychedelics as Medicine Report: Third Edition; Seattle City Council passes resolution to decriminalise psychedelics; 24 hour countdown to PSYCH Investor Summit: Data & Technology
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round
Tryp Therapeutics’ CEO Greg McKee on the next wave of psychedelic medicines; The worldview-changing drugs poised to go mainstream;
The DEA bolsters bolsters support for psychedelic research
RYAH Group's CEO Gregory Wagner on drug delivery through IoT
Awakn Life Sciences to conduct ketamine trials for gambling addiction
California bill to legalise psychedelics shelved until 2022
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.